✦ LIBER ✦

P048 Correlation of hypothyroidism and survival in patients with advanced renal cell carcinoma treated with first-line sunitinib

✍ Scribed by Cruz, P.; López, D.; Pinto, Á.

Book ID: 122426047
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 62 KB
Volume: 12
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(13)62373-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P048 Clinical hypothyroidism as a progno

P048 Clinical hypothyroidism as a prognostic factor for advanced renal cell carcinoma treated with sunitinib: A retrospective analysis

✍ Sym, S.J.; Park, J.; Hong, J.; Ahn, H.K.; Cho, E.K.; Jung, H.; Yoon, S.J.; Lee, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

7154 POSTER Hypothyroidism and Macrocyto

7154 POSTER Hypothyroidism and Macrocytosis as Surrogate Markers for Response and Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib as First-line Therapy

✍ Pinto, A.; Moreno, V.; Aguayo, C.; Garrido, M.; Espinosa, E. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

7120 A retrospective review of treatment

7120 A retrospective review of treatment discontinuation and survival in patients with advanced renal cell carcinoma treated with sunitinib or sorafenib

✍ Liu, Z.; Zheng, J.; Riedel, A.A.; Johnson, J.; Burke, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

P041 Long and very long progression free

P041 Long and very long progression free survival in patients with metastatic clear renal cell carcinoma treated with Sunitinib

✍ Gamulin, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Single nucleotide polymorphism associati

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

✍ Jesus Garcia-Donas; Emilio Esteban; Luis Javier Leandro-García; Daniel E Castell 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 181 KB

Phase II Randomized Trial Comparing Sequ

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

✍ Motzer, R. J.; Barrios, C. H.; Kim, T. M.; Falcon, S.; Cosgriff, T.; Harker, W. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 282 KB